KR20230026493A - Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법 - Google Patents

Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법 Download PDF

Info

Publication number
KR20230026493A
KR20230026493A KR1020237002565A KR20237002565A KR20230026493A KR 20230026493 A KR20230026493 A KR 20230026493A KR 1020237002565 A KR1020237002565 A KR 1020237002565A KR 20237002565 A KR20237002565 A KR 20237002565A KR 20230026493 A KR20230026493 A KR 20230026493A
Authority
KR
South Korea
Prior art keywords
rcc
cancer
lenvatinib
hif
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237002565A
Other languages
English (en)
Korean (ko)
Inventor
로돌포 플뢰리 페리니
일레인 엠. 피네이루
자클린 빌레만 로게리오
Original Assignee
머크 샤프 앤드 돔 엘엘씨
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 엘엘씨, 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 머크 샤프 앤드 돔 엘엘씨
Publication of KR20230026493A publication Critical patent/KR20230026493A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020237002565A 2020-06-22 2021-06-21 Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법 Pending KR20230026493A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063042307P 2020-06-22 2020-06-22
US63/042,307 2020-06-22
US202163146915P 2021-02-08 2021-02-08
US63/146,915 2021-02-08
PCT/US2021/038172 WO2021262563A1 (en) 2020-06-22 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib

Publications (1)

Publication Number Publication Date
KR20230026493A true KR20230026493A (ko) 2023-02-24

Family

ID=79281740

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002565A Pending KR20230026493A (ko) 2020-06-22 2021-06-21 Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법

Country Status (11)

Country Link
US (1) US20230210838A1 (cg-RX-API-DMAC7.html)
EP (2) EP4168008B1 (cg-RX-API-DMAC7.html)
JP (1) JP7750884B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230026493A (cg-RX-API-DMAC7.html)
CN (1) CN115803629A (cg-RX-API-DMAC7.html)
AU (1) AU2021296151A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026094A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183852A1 (cg-RX-API-DMAC7.html)
ES (1) ES3072250T3 (cg-RX-API-DMAC7.html)
MX (2) MX2022016406A (cg-RX-API-DMAC7.html)
WO (1) WO2021262563A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4425678A1 (en) 2023-02-28 2024-09-04 LG Energy Solution, Ltd. Separator for electrochemical device and electrochemical device comprising same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
US20240327929A1 (en) * 2021-08-12 2024-10-03 Merck Sharp & Dohme Llc Dosage regimen for administration of belzutifan
JPWO2024204679A1 (cg-RX-API-DMAC7.html) * 2023-03-31 2024-10-03

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
HUE025742T2 (hu) 2003-12-25 2016-04-28 Eisai R&D Man Co Ltd 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
EP3417851B1 (en) 2013-09-09 2020-07-22 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
EP3866927A4 (en) * 2018-10-17 2022-07-27 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4425678A1 (en) 2023-02-28 2024-09-04 LG Energy Solution, Ltd. Separator for electrochemical device and electrochemical device comprising same

Also Published As

Publication number Publication date
MX2022016406A (es) 2023-01-30
MX2025014865A (es) 2026-01-07
EP4168008A4 (en) 2024-08-07
EP4775271A2 (en) 2026-07-15
BR112022026094A2 (pt) 2023-01-17
CN115803629A (zh) 2023-03-14
ES3072250T3 (en) 2026-06-30
JP2023531675A (ja) 2023-07-25
JP7750884B2 (ja) 2025-10-07
AU2021296151A1 (en) 2023-02-02
EP4168008A1 (en) 2023-04-26
EP4168008B1 (en) 2026-03-18
CA3183852A1 (en) 2021-12-30
WO2021262563A1 (en) 2021-12-30
US20230210838A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
ES2904880T3 (es) Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
EP4168008B1 (en) A combination of belzutifan and lenvatinib for use in treating cancer
US11395821B2 (en) Treatment of EGFR-driven cancer with fewer side effects
JP6464085B2 (ja) 神経膠芽腫の治療のための併用療法
JP2020040992A (ja) ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法
US20230181565A1 (en) Crenolanib combination therapy
JP2026079825A (ja) 癌の治療のための、PD-1、TGFβ、及びTIGITの組み合わせ阻害
JP7579636B2 (ja) 膵がん治療のための組み合わせ治療薬
Scaringi et al. Combining molecular targeted agents with radiation therapy for malignant gliomas
JP2024527109A (ja) Kras変異体がんの処置のための方法および組成物
Paudel et al. Targeting lung cancer using advanced drug delivery systems
WO2023100131A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
JP2023531930A (ja) PD-1アンタゴニスト、HIF-2α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法
JP6754785B2 (ja) 免疫治療投与レジメンおよびその組合せ
RU2858600C2 (ru) Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли
JP7504106B2 (ja) がんの処置のための組合せ物
Steendam et al. Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma
CN109963847A (zh) 治疗实体瘤的方法
HK40087480A (en) Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib
JP2016502974A (ja) Pi3k/akt阻害剤化合物とher3/egfr阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用
US20210113692A1 (en) Dosing regimen
JP2020510058A (ja) トリフルリジン/チピラシル塩酸塩、抗腫瘍白金錯体、及び免疫チェックポイント調節剤の新規組み合わせ物
US20210346520A1 (en) Methods of using intravenous rexin-g: a tumor-targeted retrovector encoding a dominant-negative cyclin g1 (ccng1) inhibitor for advanced pancreatic cancer
EP4637821A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
WO2024231875A1 (en) Hpk1 inhibitor for use in the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000